2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider Buying

Recursion Pharmaceuticals' approach to drug discovery could advance the industry. Fiverr is implementing a strategy shift that may help it bounce back from recent headwinds.

The Motley Fool • 18 hours ago

Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note

Recursion Pharmaceuticals (RXRX) closed at $3.23 in the latest trading session, marking a +2.22% move from the prior day.

Zacks Investment Research • Jun 24, 2026

Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today

The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $3.18, representing a -3.34% change from its previous close.

Zacks Investment Research • Jun 16, 2026

Recursion Pharmaceuticals: Short-Trade Crowded But Near-Term Squeeze Not Guaranteed

Recursion Pharmaceuticals, Inc. is advancing REC-1245, an RBM39 degrader, in the DHALIA trial in solid tumors, with Q1'26 earnings noting no dose-limiting toxicities so far. Initial DHALIA trial data are based on a small cohort of 16 patients, with the drug only now reaching relevant dose levels for anti-tumor activity, limiting conclusions. A H2 '26 update from DHALIA could confirm anti-tumor activity of REC-1245, but might not have enough additional data to go beyond that.

Seeking Alpha • Jun 12, 2026

Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.06, moving 5.12% from the previous trading session.

Zacks Investment Research • Jun 10, 2026

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 9, 2026

Recursion Pharmaceuticals (RXRX) Up 16.2% Since Last Earnings Report: Can It Continue?

Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Jun 5, 2026

Recursion to Participate in Upcoming Investor Conferences

Salt Lake City, UT, June 02, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in an upcoming investor conference: Goldman Sachs 47th Annual Global Healthcare Conference — Tuesday, June 9, 2026 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com .  About Recursion Recursion (NASDAQ: RXRX) is a clinical-stage TechBio company decoding biology to radically improve lives.

GlobeNewsWire • Jun 2, 2026

Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Salt Lake City, UT, May 29, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on May 26, 2026, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 2,991,840 shares of its class A common stock in the aggregate to 33 new employees under Recursion's 2024 Inducement Equity Incentive Plan (the “2024 Plan”). Each award was granted as an inducement material to the employee's commencement of employment with Recursion, or a subsidiary of Recursion, pursuant to Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire • May 29, 2026

Altitude Lab Portfolio Companies Surpass $205 Million in Funding, Marking a New Era for Early-Stage Biotechs in Salt Lake City

Altitude Lab portfolio companies surpass $205M in funding as startups advance clinical trials, sign global pharma deals, and reshape early-stage biotech.

GlobeNewsWire • May 19, 2026